Imohgen Alo rang the bell at John Hunter Children's Hospital on Friday to mark the end of her cancer treatment. The NSW Lake ...

Citius Oncology Inc. has commercially launched Lymphir, a treatment for Stage I–III cutaneous T-cell lymphoma, the Cranford-based firm announced Dec. 1. In August 2024, the U.S. Food and Drug ...

Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive ...

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

Immunotherapy uses the power of your immune system to fight your cancer. There are several types of immunotherapies. They include antibody therapies and CAR T-cell therapy. Immunotherapies are among ...

What started out as shoulder pain turned into a living nightmare for a Melbourne girl and her family after doctors discovered a large mass in the eight-year-old’s chest, which turned out to be a rare ...

Initiating first-in-human Phase 1 trial in H1 of 2024 PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) ...